financetom
Business
financetom
/
Business
/
Eton Pharmaceuticals Says US Patent Granted for ET-600 Formulation
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Eton Pharmaceuticals Says US Patent Granted for ET-600 Formulation
Feb 7, 2025 4:23 AM

07:07 AM EST, 02/07/2025 (MT Newswires) -- Eton Pharmaceuticals ( ETON ) said Friday that the US Patent and Trademark Office has granted a patent for the formulation of its ET-600 product candidate, a desmopressin oral solution being developed as potential treatment for diabetes insipidus.

The company said the patent expires in 2044 and is expected to be listed in the FDA's Orange Book once ET-600 is approved.

Eton said it has another patent application related to the ET-600 product that is currently under review.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved